治疗前血清白蛋白和突变负荷作为免疫检查点阻断反应的生物标志物。
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade.
作者信息
Yoo Seong-Keun, Chowell Diego, Valero Cristina, Morris Luc G T, Chan Timothy A
机构信息
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, 44195, USA.
The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
出版信息
NPJ Precis Oncol. 2022 Apr 7;6(1):23. doi: 10.1038/s41698-022-00267-7.
The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.
细胞因子和蛋白质稳定载体（如血清白蛋白）对肿瘤免疫检查点阻断（ICB）反应的影响尚未完全明确。通过对16种癌症类型的1714例患者进行研究，我们发现，治疗前血清白蛋白水平较高可预测ICB治疗后肿瘤影像学反应良好，且呈剂量依赖性。血清白蛋白是一种候选生物标志物，可与肿瘤突变负荷（TMB）相结合以提高预测能力，在白蛋白水平高/TMB水平高的组中，肿瘤对ICB的反应率约为49%。
Zotero 插件